Skip to main content

Granuloma

1
Pipeline Programs
2
Companies
10
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
BetadinePhase 41 trial
Active Trials
NCT02116608Completed26Est. Sep 2019
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
AluminumN/A5 trials
Active Trials
NCT07221162Recruiting140Est. Nov 2026
NCT06680479Suspended30Est. Apr 2028
NCT06796686Recruiting42Est. Jan 2027
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Colorado TherapeuticsBetadine
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum
Allergy TherapeuticsAluminum

Clinical Trials (10)

Total enrollment: 838 patients across 10 trials

Treatment of Tracheostomy Granulomas

Start: Sep 2014Est. completion: Sep 201926 patients
Phase 4Completed

Tdap Vaccine in Post-Partum Women

Start: Oct 2012Est. completion: Aug 201555 patients
Phase 4Completed

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

Start: Jan 2019Est. completion: Jul 2020399 patients
Phase 2Completed

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Start: Dec 2025Est. completion: Nov 2026140 patients
Phase 1Recruiting

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Start: Apr 2025Est. completion: Apr 202830 patients
Phase 1Suspended

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

Start: Mar 2025Est. completion: Jan 202742 patients
Phase 1Recruiting

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

Start: Jan 2023Est. completion: Jul 202551 patients
Phase 1Completed

Phase I STEBVax in Healthy Adults

Start: Feb 2011Est. completion: Mar 201529 patients
Phase 1Completed

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

Start: Apr 1999Est. completion: May 200150 patients
Phase 1Completed

Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas

Start: Sep 2022Est. completion: Feb 202316 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 838 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.